Background: While plasma-derived concentrates containing large amounts of von Willebrand factor (VWF) are effective in treating von Willebrand disease (VWD), optimal dosing remains to be fully characterized. Objectives: To determine the feasibility of dosing Haemate P® VWF/factor VIII (FVIII) concentrate based on pharmacokinetics (PK) in the management of surgical subjects with VWD. Methods: VWD subjects scheduled for elective surgery were enrolled in a prospective multicenter open-label cohort study. A pre-operative loading dose of VWF/FVIII concentrate based upon prior individual subject PK analysis was administered followed by postoperative therapeutic/ maintenance infusions. Results: Twenty-eight subjects with types 1, 2A or 3 VWD and one with type 2 M were enrolled. Median in vivo recovery of VWF ristocetin cofactor (VWF:RCo) was 1.9 IU dL-1 (IU kg-1) -1 with an interquartile range (IQR) of 1.6-2.5 IU dL-1 (IU kg-1)-1. Median response, half-life and clearance were 74.0% (IQR, 55.5-100%), 15.6h (IQR, 9.0-28.4h) and 3.26 mL kg-1 h-1 (IQR, 2.29-5.21mL kg-1 h-1), respectively. A PK-guided median VWF:RCo loading dose of 62.4 IU kg-1 (IQR, 50.1-87.0 IU kg-1) was administered. Postoperative mean trough VWF:RCo levels of 62-73 IU dL-1 were sufficient to prevent bleeding. Investigators rated hemostasis excellent or good in 96.3% of subjects on the day of surgery and 100% on the next day and on day 14. A subject with multiple risk factors developed pulmonary embolism, which resolved without sequelae. Conclusions: Haemate P® provided effective and safe hemostasis in VWD subjects undergoing elective surgery. Selection of Haemate® P loading dose on the basis of VWF PK proved feasible.

Von Willebrand factor/factor VIII concentrate (Haemate(R) P) dosing based on pharmacokinetics : a prospective multicenter trial in elective surgery / S. Lethagen, P.A. Kyrle, G. Castaman, S. Haertel, P.M. Mannucci. - In: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. - ISSN 1538-7933. - 5:7(2007), pp. 1420-1430.

Von Willebrand factor/factor VIII concentrate (Haemate(R) P) dosing based on pharmacokinetics : a prospective multicenter trial in elective surgery

P.M. Mannucci
Ultimo
2007

Abstract

Background: While plasma-derived concentrates containing large amounts of von Willebrand factor (VWF) are effective in treating von Willebrand disease (VWD), optimal dosing remains to be fully characterized. Objectives: To determine the feasibility of dosing Haemate P® VWF/factor VIII (FVIII) concentrate based on pharmacokinetics (PK) in the management of surgical subjects with VWD. Methods: VWD subjects scheduled for elective surgery were enrolled in a prospective multicenter open-label cohort study. A pre-operative loading dose of VWF/FVIII concentrate based upon prior individual subject PK analysis was administered followed by postoperative therapeutic/ maintenance infusions. Results: Twenty-eight subjects with types 1, 2A or 3 VWD and one with type 2 M were enrolled. Median in vivo recovery of VWF ristocetin cofactor (VWF:RCo) was 1.9 IU dL-1 (IU kg-1) -1 with an interquartile range (IQR) of 1.6-2.5 IU dL-1 (IU kg-1)-1. Median response, half-life and clearance were 74.0% (IQR, 55.5-100%), 15.6h (IQR, 9.0-28.4h) and 3.26 mL kg-1 h-1 (IQR, 2.29-5.21mL kg-1 h-1), respectively. A PK-guided median VWF:RCo loading dose of 62.4 IU kg-1 (IQR, 50.1-87.0 IU kg-1) was administered. Postoperative mean trough VWF:RCo levels of 62-73 IU dL-1 were sufficient to prevent bleeding. Investigators rated hemostasis excellent or good in 96.3% of subjects on the day of surgery and 100% on the next day and on day 14. A subject with multiple risk factors developed pulmonary embolism, which resolved without sequelae. Conclusions: Haemate P® provided effective and safe hemostasis in VWD subjects undergoing elective surgery. Selection of Haemate® P loading dose on the basis of VWF PK proved feasible.
Factor VIII; Hereditary diseases; Postoperative hemorrhage; Prospective studies; Surgical hemostasis; Von Willebrand factor
Settore MED/09 - Medicina Interna
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/43167
Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 101
  • ???jsp.display-item.citation.isi??? 97
social impact